The Philadelphia-based biotech develops gene therapies to treat rare single-gene disorders affecting the central nervous system.
Lead candidates are: PBGM01 for GM1 gangliosidosis, PBFT02 for frontotemporal dementia and PBKR03 for Krabbe disease.
One of the founders is University of Pennsylvania’s James Wilson, a pioneer in gene therapies.
2019 Financials: Operating Expenses: $37.2M (+176%); Net Loss: ($45.6M) (-256%); Cash Burn: ($39.9M) (-115%).
https://seekingalpha.com/news/3537426-passage-bio-on-deck-for-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.